ClinicalTrials.gg
CompletedNCT04546776CoPSUpdated Jun 17, 2025

COVID-19 Persistence in Stool

An observational study in SARS-CoV Infection, sponsored by Quadram Institute Bioscience. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Quadram Institute Bioscience · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom — 2 open to participants now, 2 under way, 1 of them phase 3. Severe Acute Respiratory Syndrome · United Kingdom.

Enrollment
6th of 11
105 · median 105
Started
2020
with 14 others
Observational
11 of 24
1 open now
Registered
11th of 24
by date

Among the 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom, this one is the 6th largest by enrollment of the 11 observational ones that give a count, is one of 15 that started in 2020, is one of 11 observational ones, and was the 11th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

2 of the 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Severe Acute Respiratory Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a longitudinal study in which participants that have been confirmed by a National Health Service (NHS) swab test as COVID-19 positive will be asked to provide faecal and saliva samples, and complete short health/lifestyle questionnaires at the time of sampling (referred to as a sample set). The number of sample sets collected from any participant will be dependent on how long the SARS-CoV-2 virus persists within the stool. The investigators aim to collect a minimum of 4 and a maximum of 8 sample sets, and will target all COVID-19-positive subjects, with the exception of those severally ill (e.g. in the intensive care unit (ICU)). The investigators aim to recruit a minimum of 100 and up to 200 participants. To obtain the desired numbers, it may be necessary to continue recruitment during any further United Kingdom (UK) COVID-19 infection peaks.

Read the detailed description

Approaching participants will mainly be performed in two ways:

  1. the Norfolk and Norwich University Hospital (NNUH) online booking system for SARS-CoV-2 testing will have a link to the Quadram Institute Bioscience (QIB) study webpage, which will include the Participant Information Sheet (PIS). When the NHS testing service informs individuals of their test results by text message, the QIB study page Uniform Resource Locator (URL) will be added to the end of the text message for COVID-19 'positive' results. In addition, testing service staff will remind the potential participants of the study if they contact individuals by telephone to inform them of positive COVID-19 results from the test-centre swabs. During this call, potential participants will be asked to provide verbal consent for the study team to contact them for arranging a study talk. Potential participants will be able to contact QIB directly to express interest by email or phone, and can contact QIB to request a hard copy of the PIS be posted to them.
  2. NNUH staff will approach in-ward patients positive for COVID-19. Should the patients be interested in learning more, a NNUH staff member will provide them with a copy of the PIS and be available to answer any questions the patients may have. Fully informed written consent of hospitalised COVID-19 patients will be performed by an NNUH nurse using the study consent form.

    • Participants recruited from a non-hospital setting will be consented, using the same consent form as hospitalised patients, over the telephone/internet video by members of the study team who have received the QIB consent training.

Signed copies of these forms will be collected along with the first sample set. In both scenarios, each point will be explained and all questions will be answered to ensure that the participant is fully informed.

The investigators will also be asking participants whether they would be willing to consent to their samples being stored at the Norwich Research Park Biorepository, and whether they would consent to being re-contacted by researchers about possible future research for which they may be eligible. These are both optional, i.e. should the patient choose not to consent to either or both, they will still be able to participate in the study.

Following the recruitment of COVID-19 positive participants the investigators will ask for an initial faecal and saliva sample, and request that the participant completes a health/lifestyle questionnaire. If participants show symptoms the investigators will collect a second set of samples after 48h of symptoms disappearance (specifically, a lack of fever), whereas if participants are asymptomatic the investigators will collect the second set of samples after 7 days. For both types of participants, the investigators will then collect 2 more sample sets every 7 days (day 7: set 3, day 14: set 4). Should either sample test positive then the investigators will continue the same 7-day sampling process until both samples are negative for two consecutive sample sets, or they have given a total of eight faecal and saliva samples. At either of these points, whichever is earliest, the participant will have then completed the study

03

Conditions studied

  • SARS-CoV Infection

Keywords

  • Faeces
  • Saliva
  • Whole-genome shotgun sequencing
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Those who have tested positive for COVID-19, whether isolated at home or admitted to the Norfolk and Norwich University Hospital. Those admitted to the intensive care unit will not be eligible for the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged >18 years
  • Those that live or work within a 40-mile radius of Norwich/Norfolk and Norwich University Hospital
  • Those who are confirmed COVID-19 positive by an NHS swab test

Exclusion criteria

Exclusion Criteria:

  • Those who are admitted to an NHS Intensive Care Unit
  • Any person related to, or living with, any member of the study team
  • Those who are part of the Line Manager/supervisory structure of the Chief Investigators
  • Those who are unable to provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (actual)
Patient registry
No

Groups and cohorts

  • Faecal and saliva sampling

    A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period

06

What researchers measure

Primary outcomes

  1. Prevalence and persistence of the SARS-CoV-2 virus in the faeces, and change in associated health status

    To verify the prevalence and persistence (starting from symptom onset/diagnosis, and up to seven weeks after recovery) of the SARS-CoV-2 virus in the faeces of people diagnosed with COVID-19 infection.

    Time frame: Weekly for a maximum of 8 weeks

Secondary outcomes

  1. Viral strain-specific prevalence, associated with change in health status

    To use whole-genome sequencing (WGS) to type COVID-19 at the strain level to verify whether different viral strains have a different persistence in stool across participants

    Time frame: Weekly for a maximum of 8 weeks

  2. Biogeographical viral strain identification, associated with change in health status

    To use whole-genome sequencing (WGS) to type COVID-19 at the strain level to verify whether the viral strain(s) found in the gastrointestinal tract are identical to those found in the respiratory tract of participants

    Time frame: Weekly for a maximum of 8 weeks

  3. Create a SARS-CoV-2 biological sample repository

    To create a repository of material (faeces and saliva) and associated data that will be used to understand the association between gastrointestinal health and SARS-CoV-2 infection in future research.

    Time frame: Through study completion, up to two years

07

Study locations

3 sites
  • James Paget University Hospital Foundation Trust
    Great Yarmouth, Norfolk NR31 6LA, United Kingdom
  • Quadram Institute Bioscience
    Norwich, Norfolk NR4 7UQ, United Kingdom
  • Norfolk and Norwich University Hospital Foundation Trust
    Norwich, Norfolk NR4 7UY, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Nov 2024, 50 months.

Of 70 non-industry observational studies under Severe Acute Respiratory Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 50 months is above that.

Counting every sponsor, half of 79 studies reached it within 12 months; a quarter within 4 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 14, 2020
StartActual
Sep 8, 2020
Primary completionActual
Nov 30, 2024
CompletionActual
May 9, 2025
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04546776
Lead sponsor
Quadram Institute Bioscience
Collaborators
Norfolk and Norwich University Hospitals NHS Foundation Trust, James Paget University Hospital NHS Foundation Trust
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 8, 2020
Primary completion
Nov 30, 2024
Completion
May 9, 2025
Last update
Jun 17, 2025

Study contacts

Arjan Narbad, BSc, PhD
principal investigator · Quadram Institute Bioscience
Ngozi Franslem-Elumogo, MBBS, DTM&H, FRCPath
principal investigator · Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Andreas Brodbeck, PhD, FRCA, FICM
principal investigator · James Paget University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion